Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19190038 | 0.88 | ALDH1A1 (0.58) | ALDH1A1KMT2AMEN1TSHRMAPK10 | |
| SCHEMBL6171639 | 0.85 | ALDH1A1 (0.78) | ALDH1A1KMT2AMEN1TSHRMAPK10 | |
| SCHEMBL5707095 | 0.83 | MTNR1A (0.69) | ALDH1A1TSHRMTNR1AMTNR1B | |
| SCHEMBL7366509 | 0.82 | KMT2A (0.53) | ALDH1A1KMT2ATSHRPOLB | |
| SCHEMBL5718761 | 0.81 | ALDH1A1 (0.51) | ALDH1A1KMT2AMEN1TSHRMAPK10 | |
| SCHEMBL23997386 | 0.81 | ALDH1A1 (0.58) | ALDH1A1KMT2AMEN1TSHRMAPK10 | |
| SCHEMBL30336782 | 0.81 | ALDH1A1 (0.58) | ALDH1A1KMT2AMEN1TSHRMAPK10 | |
| SCHEMBL5681740 | 0.80 | ALDH1A1 (0.85) | ALDH1A1KMT2AMEN1TSHRMAPK10 | |
| SCHEMBL2009538 | 0.80 | ALDH1A1 (0.65) | ALDH1A1KMT2AMEN1TSHRMAPK10 | |
| SCHEMBL27941200 | 0.80 | ALDH1A1 (0.56) | ALDH1A1KMT2AMEN1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236084-B2 | Substituted azaindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-01 | — | — | US | disclosed |
| EP-3649127-B1 | SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-08 | — | — | EP | disclosed |
| US-20210188840-A1 | NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | US | disclosed |
| WO-2019008011-A1 | NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-10 | — | — | WO | disclosed |
| WO-2004050646-A1 | 1, 2, 5-THIADIAZOLIDIN-3-ONE 1, 1 DIOXIDE DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE PTP1B | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236084-B2 | Substituted azaindoline derivatives as NIK inhibitors | MAP3K14, NFKBIA, MAP3K15 | ALDH1A1 3603/4885KMT2A 816/4885MEN1 1465/4885 |
| US-20210188840-A1 | NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | NFKBIA, IKBKG, MAP3K14 | ALDH1A1 3864/4885KMT2A 833/4885MEN1 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.